Neuromodulation is a rapidly growing market, with significant investments in pelvic health, including Boston Scientific's $3.4 billion acquisition of Axonics and funding for Amber Therapeutics, Neuspera Medical, and Avation Medical. David Constantine, Co-Founder and CEO of Juniper Biomedical, has leveraged his career experiences to drive their mission of revolutionizing pelvic health through precision neuromodulation. His passion for impactful work highlights the importance of finding meaningful career paths that motivate and sustain us through challenges. This conversation with David underscored the timely relevance of their innovative approach in transforming patient outcomes.
